

Supplementary Table S1. Demographic, clinical and treatment characteristics according to methotrexate intolerance severity (MISA and MISA-CP categories).

| Variable | MISA <1 n=45 | MISA ≥1 n=58 | p-value | MISA-CP <4 n=80 | MISA-CP ≥4 n=23 | p-value |
|---|-----------------|-----------------|-------------|--------------------|--------------------|--------------|
| Age, years, mean, (SD) | 49 (12) | 47 (11) | 0.30 | 50 (12) | 42 (10) | 0.002 |
| Female sex, n (%) | 32 (71) | 43 (74) | 0.73 | 58 (73) | 17 (74) | 0.89 |
| BMI, kg/m ² , mean (SD) | 30 (5) | 28 (5) | 0.02 | 29 (5) | 28 (5) | 0.15 |
| PsA duration, years, median (IQR) | 4 (7) | 4 (10) | 0.41 | 4 (7) | 4 (10) | 0.27 |
| TJC (0-68), median (IQR) | 2 (9) | 1 (4) | 0.21 | 2 (7) | 0 (3) | 0.51 |
| SJC (0-66), median (IQR) | 0 (1) | 0 (1) | 0.69 | 0 (1) | 0 (0) | 0.23 |
| PGA (0-100), median (IQR) | 50 (60) | 50 (35) | 0.36 | 50 (50) | 50 (30) | 0.46 |
| PhGA (0-100), median (IQR) | 30 (35) | 20 (30) | 0.26 | 30 (40) | 20 (20) | 0.77 |
| DAPSA, median (IQR) | 19 (24) | 18 (10) | 0.76 | 19 (18) | 17 (6) | 0.53 |
| HAQ-DI (0-3), median (IQR) | 1 (1) | 1 (1) | 0.41 | 1 (1) | 1 (1) | 0.61 |
| At least one comorbidity, n (%) | 22 (49) | 28 (48) | 0.95 | 42 (53) | 8 (35) | 0.13 |
| Current biological therapy, n (%) | 15 (33) | 28 (48) | 0.13 | 32 (40) | 11 (48) | 0.50 |
| Current MTX dose, mg/week, mean (SD) | 15 (0) | 15 (5) | 0.15 | 15 (0) | 15 (5) | 0.053 |
| MTX treatment duration, months, mean (SD) | 24 (72) | 41 (78) | 0.32 | 28 (75) | 50 (75) | 0.17 |
| MTX administration route | | | | | | |
| Oral, n (%) | 17 (38) | 31 (53) | 0.11 | 39 (49) | 9 (39) | 0.42 |
| Subcutaneous, n (%) | 28 (62) | 27 (47) | | 41 (52) | 14 (61) | |

MISA≥1 indicates MTX intolerance; MISA-CP≥4 indicates moderate-to-severe intolerance.

BMI: Body Mass Index; DAPSA: Disease Activity in Psoriatic Arthritis; HAQ-DI: Health Assessment Questionnaire-Disability Index; IQR: interquartile range; MISA: Methotrexate Intolerance Severity Assessment; MISA-CP: MISA-cross product; MTX: methotrexate; PGA: patient global assessment; PhGA: physician global assessment; PsA: psoriatic arthritis; SD: standard deviation; SJC: swollen joint count; TJC: tender joint count.

Supplementary Table S2. Univariable and multivariable logistic regression analyses for factors associated with methotrexate intolerance (MISA ≥1 and MISA-CP ≥4).

| Variables | MISA ≥1 | | | | | | MISA-CP ≥4 | | | | | |
|-----------------------|----------------------|-----------|-------------|------------------------|-----------|-------------|----------------------|-----------|--------------|------------------------|-----------|-------------|
| | Univariable analyses | | | Multivariable analyses | | | Univariable analyses | | | Multivariable analyses | | |
| | OR | 95 % CI | p | OR | 95 % CI | p | OR | 95 % CI | p | OR | 95 % CI | p |
| Age | 0.98 | 0.95-1.02 | 0.33 | | | | 0.94 | 0.90-0.98 | 0.004 | 0.94 | 0.89-0.99 | 0.02 |
| Sex (female vs. male) | 1.16 | 0.49-2.79 | 0.73 | | | | 1.08 | 0.38-3.08 | 0.89 | | | |
| BMI | 0.91 | 0.84-0.99 | 0.03 | 0.91 | 0.83-1.00 | 0.04 | 0.93 | 0.84-1.03 | 0.15 | | | |
| DAPSA | 0.98 | 0.95-1.01 | 0.21 | | | | 0.98 | 0.94-1.02 | 0.32 | | | |
| Current MTX dose | 1.10 | 0.96-1.25 | 0.16 | | | | 1.13 | 0.98-1.32 | 0.10 | | | |

BMI: Body Mass Index; CI: confidence interval; DAPSA: Disease Activity in Psoriatic Arthritis; MTX: methotrexate; OR: odds ratio.

**Supplementary to:
Methotrexate intolerance in psoriatic arthritis: prevalence and associated factors**

H. CINAKLI, M. KARA, G. ALP